Warnex Inc.

Warnex Inc.

April 05, 2007 07:00 ET

Warnex to perform pharmacogenetic and bioanalytical services for Novartis Canada's Gleevec® Monitoring Program

LAVAL, QC, April 5 - Warnex Inc. (TSX: WNX) today announced that it
will perform pharmacogenetic and bioanalytical services for Novartis
Pharmaceuticals Canada Inc. ("Novartis"), a leader in the healthcare field.
These services involve Novartis' Blood Level Monitoring Program for Gleevec®
(imatinib mesylate), a medication approved for the treatment of patients with
chronic myeloid leukemia and gastro-intestinal stromal tumours.

"Pharmaceutical and biotechnology companies are increasingly using
genetic tests to determine patient response to their medication," said Mark
Busgang, President and CEO of Warnex. "This contract demonstrates our ability
to leverage our genomic expertise and our bioanalytical capabilities to
provide a unique, comprehensive service offering to pharmaceutical companies."

The goal of the Gleevec® Blood Level Monitoring Program is to provide
practicing physicians with clinically relevant information to help monitor and
optimize patient treatment. Physicians may monitor their patients for reasons
of adherence concerns, suspicion of drug-drug interaction, a less than
expected response to Gleevec® or side effects that are unusually severe for
the dose of taken.

Warnex's Bioanalytical Services division will test Gleevec® blood
levels to help identify non-adherence or suboptimal dosing. Warnex uses
state-of-the-art high performance liquid chromatography coupled with mass
spectrometry (LC/MS/MS), a highly specific and sensitive method to perform
bioanalysis in blood samples.

In addition, Warnex's Medical Laboratories division will use
pharmacogenetics to determine if the patients have specific chromosomal
abnormalities in order to evaluate the effect of the medication based on
genetic conditions. Warnex's diagnostic tests are performed using the highly
sensitive and reliable polymerase chain reaction (PCR) technology to detect
genetic abnormalities during the course of a patient's treatment.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting
public health by providing laboratory services to the pharmaceutical and
healthcare sectors. Warnex's analytical services division provides
pharmaceutical and biotechnology companies with a variety of quality control
services, including traditional chemistry, chromatography, microbiology,
method development and validation, and stability studies. Warnex's
bioanalytical services group specializes in bioequivalence and bioavailability
studies for clinical trials. Warnex's medical laboratories division focuses on
genetic and biochemical testing for the healthcare industry and has extensive
expertise in genetic testing for human identification, molecular diagnostics,
and pharmacogenetics.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk, volatility of share price, strategic alternatives for the
pathogen detection division, and other important factors that could cause
actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis in the 2006 Annual
Report, which can be found at www.sedar.com. Consequently, actual results may
differ materially from the anticipated results expressed in these
forward-looking statements.

Contact Information